Elicio Therapeutics Q1 net loss widens, cash runway extends into Q4 2026

Elicio Therapeutics

11/05/2026 21:16

Overview

US cancer immunotherapy developer reported Q1 net loss widened slightly from prior year

R&D expenses fell as Phase 2 trial patients moved to follow-up phase

Company raised $13 mln in Q1 and Q2 to date, extending cash runway into Q4 2026

Outlook

Company expects cash runway to support operations into Q4 2026, beyond Phase 2 DFS readout

Elicio anticipates Phase 2 AMPLIFY-7P primary DFS analysis for ELI-002 7P mid-year 2026

Company plans to request FDA meeting post-DFS analysis to align on Phase 3 trial design

Result Drivers

LOWER CLINICAL TRIAL COSTS - R&D expenses decreased as patients in the Phase 2 AMPLIFY-7P trial moved from active dosing to follow-up phase

HIGHER PERSONNEL COSTS - G&A expenses rose due to increased company headcount and personnel costs

Company press release: ID:nGNXcdkm8r

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$11.82 mln
Q1 Basic EPS
-$0.65
Q1 Income from Operations
-$10.60 mln
Q1 Operating Expenses
$10.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Elicio Therapeutics Inc is $17.50, about 76.6% above its May 8 closing price of $9.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)